JP5919202B2 - 医療用一酸化炭素放出レニウム化合物 - Google Patents

医療用一酸化炭素放出レニウム化合物 Download PDF

Info

Publication number
JP5919202B2
JP5919202B2 JP2012556409A JP2012556409A JP5919202B2 JP 5919202 B2 JP5919202 B2 JP 5919202B2 JP 2012556409 A JP2012556409 A JP 2012556409A JP 2012556409 A JP2012556409 A JP 2012556409A JP 5919202 B2 JP5919202 B2 JP 5919202B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
alkyl
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012556409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521316A (ja
JP2013521316A5 (enExample
Inventor
ゾビ、ファビオ
アルベルト、ロジェ
クロマー、ルーカス
Original Assignee
ユニバーシティー オブ チューリッヒ
ユニバーシティー オブ チューリッヒ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ チューリッヒ, ユニバーシティー オブ チューリッヒ filed Critical ユニバーシティー オブ チューリッヒ
Publication of JP2013521316A publication Critical patent/JP2013521316A/ja
Publication of JP2013521316A5 publication Critical patent/JP2013521316A5/ja
Application granted granted Critical
Publication of JP5919202B2 publication Critical patent/JP5919202B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012556409A 2010-03-08 2011-03-04 医療用一酸化炭素放出レニウム化合物 Active JP5919202B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10002342.3 2010-03-08
EP10002342 2010-03-08
PCT/EP2011/001077 WO2011110315A1 (en) 2010-03-08 2011-03-04 Carbon monoxide releasing rhenium compounds for medical use

Publications (3)

Publication Number Publication Date
JP2013521316A JP2013521316A (ja) 2013-06-10
JP2013521316A5 JP2013521316A5 (enExample) 2014-04-24
JP5919202B2 true JP5919202B2 (ja) 2016-05-18

Family

ID=43828395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556409A Active JP5919202B2 (ja) 2010-03-08 2011-03-04 医療用一酸化炭素放出レニウム化合物

Country Status (6)

Country Link
US (2) US9512156B2 (enExample)
EP (1) EP2545064B1 (enExample)
JP (1) JP5919202B2 (enExample)
CN (1) CN102791724A (enExample)
CA (1) CA2792319A1 (enExample)
WO (1) WO2011110315A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134710B2 (ja) * 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
EP2868348A1 (en) 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
US20070207217A1 (en) 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CA2534415A1 (en) 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
EP1675626A2 (en) * 2003-10-20 2006-07-05 Universität Zürich Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents
ATE443070T1 (de) * 2004-01-08 2009-10-15 Univ Zuerich Metallkomplexe mit vitamin b12 als ligand
WO2007073225A1 (en) 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2009013612A1 (en) 2007-07-24 2009-01-29 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos, Lda. Prevention of gastric ulcery by carbon monoxide

Also Published As

Publication number Publication date
US20170071981A1 (en) 2017-03-16
WO2011110315A1 (en) 2011-09-15
CA2792319A1 (en) 2011-09-15
EP2545064B1 (en) 2020-05-06
US9512156B2 (en) 2016-12-06
US20120328712A1 (en) 2012-12-27
CN102791724A (zh) 2012-11-21
JP2013521316A (ja) 2013-06-10
EP2545064A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
ES2291759T3 (es) Ligandos piridino pentaazamacrociclicos sustituidos.
JP6336681B2 (ja) 白金化合物、組成物、及びそれらの使用
CN108619511B (zh) 一种基于阿糖胞苷小分子前药的金属有机框架载药系统的制备方法和应用
US20100291236A1 (en) Osmium compounds
JPS6094966A (ja) 医薬組成物、それに使用される１―ヒドロキシピリド―２―オンである化合物及びその塩
EA010834B1 (ru) Пиридилзамещённые порфириновые соединения и способы их применения
JP2004500321A (ja) 金属錯体を含む薬学的組成物
JP2015134798A (ja) 非対称性ビス（チオセミカルバゾン）の調製方法
US20080275019A1 (en) Metal complex protein kinase inhibitors
KR20170016933A (ko) 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물
Zobi et al. Reactivity of 17 e− complex [ReIIBr4 (CO) 2] 2− with bridging aromatic ligands. Characterization and CO-releasing properties
Miles et al. Synthesis, characterization, and anticancer activities of lipophilic pyridinecarboxaldimine platinum (II) complexes
JP5919202B2 (ja) 医療用一酸化炭素放出レニウム化合物
US20080182834A1 (en) Multi-Nuclear Metal Complexes Partially Encapsulated by Cucurbit[7-12]Urils
WO2012153253A2 (en) Aromatic compounds and metal complexes thereof
US20160096855A1 (en) Method of Treating Colorectal Cancer
JP2010530411A (ja) 白金（ｉｖ）錯体
US20160101177A1 (en) pH AND LIGHT ACTIVATED ANTI-CANCER DRUGS
CN115340543A (zh) 正离子型环蕃及其在制备清除光动力治疗残留物的药物制剂中的应用
CN108864114B (zh) 选择性a2a受体拮抗剂
JP7154528B2 (ja) ホウ素含有葉酸誘導体
ES2252449T3 (es) Nuevos complejos anionicos y neutros de rutenio (ii) que contienen oxido nitrico.
KR101394878B1 (ko) 신규한 ６핵 아렌-루테늄 나노 프리즘 케이지 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 및 치료용 약학적 조성물
KR101973456B1 (ko) 미토콘드리아에 표적화되는 수용성 화합물, 이를 포함하는 조성물 및 이의 제조방법
JP2005511497A (ja) 光反応性化合物および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160411

R150 Certificate of patent or registration of utility model

Ref document number: 5919202

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250